Lyra Therapeutics, Inc. (LYRA)
| Market Cap | 1.33M -80.2% |
| Revenue (ttm) | 398.00K -74.1% |
| Net Income | -28.92M |
| EPS | -18.62 |
| Shares Out | 1.77M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,531 |
| Average Volume | 10,256 |
| Open | 0.7100 |
| Previous Close | 0.7500 |
| Day's Range | 0.7100 - 0.7500 |
| 52-Week Range | 0.3100 - 37.5000 |
| Beta | 0.30 |
| RSI | 47.75 |
| Earnings Date | Apr 29, 2026 |
About Lyra Therapeutics
Lyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of anti-inflammatory therapies for the treatment of patients with chronic rhinosinusitis. Its technology is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company’s product candidates include LYR-210, an anti-inflammatory implantable drug matrix which is in Phase III clinical trial for the treatment of chronic rhinosinusitis (CRS); and LYR-220 for CRS patients wh... [Read more]
Financial Performance
In 2025, Lyra Therapeutics's revenue was $398,000, a decrease of -74.05% compared to the previous year's $1.53 million. Losses were -$28.92 million, -69.05% less than in 2024.
Financial StatementsNews
Lyra Therapeutics, Inc. Announces Intention to Voluntarily File Form 25 for Delisting from Nasdaq and Subsequent Deregistration with the SEC
WATERTOWN, Mass., April 17, 2026 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (the "Company") today announced its intention to voluntarily file a Form 25 Notification of Delisting with the U.S. Securit...
Lyra Therapeutics Provides Corporate Update
WATERTOWN, Mass., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (“Lyra” or the “Company”) today announced that its Board of Directors has decided to suspend further developm...
Lyra Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
– Company plans new, confirmatory Phase 3 clinical trial of LYR-210 for treatment of chronic rhinosinusitis (CRS) without nasal polyps, on path to NDA submission –
Lyra Therapeutics Announces Clinical Plan for LYR-210 and Late-Breaking Oral Presentation of Phase 3 ENLIGHTEN 2 Study
Company outlines clinical plan for LYR-210 based on FDA meeting on the path to NDA submission Positive ENLIGHTEN 2 results highlighted at the AAO-HNS 2025 Annual Meeting WATERTOWN, Mass., Oct. 06, 20...
Lyra Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
– Positive ENLIGHTEN 2 Phase 3 results announced in June 2025 propel business activities in manufacturing, regulatory strategy and ENLIGHTEN clinical dataset analysis to advance path forward for LYR-2...
Lyra Therapeutics Announces Up to Approximately $15 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules
Upfront Gross Proceeds of $5.0 Million, with Up to Approximately $9.8 Million of Additional Gross Proceeds Assuming the Cash Exercise in Full of Private Placement Warrants Upfront Gross Proceeds of $5...
Lyra Therapeutics Transcript: Study Result
Enlightened II phase III trial of LYR-210 in CRS met primary and key secondary endpoints, showing significant symptom and quality-of-life improvements with a strong safety profile. Plans are underway for FDA engagement and further studies in polyp patients.
Why Is Lyra Therapeutics Stock Surging Over 400% On Monday?
Lyra Therapeutics, Inc. LYRA released results on Monday from the ENLIGHTEN 2 Phase 3 trial of LYR-210 in adult patients with Chronic Rhinosinusitis (CRS).
Lyra Therapeutics Reports Positive Results from the ENLIGHTEN 2 Phase 3 Trial of LYR-210 Achieving Statistically Significant Results for Primary and Key Secondary Endpoints in the Treatment of Chronic Rhinosinusitis (CRS)
WATERTOWN, Mass., June 02, 2025 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (“Lyra” or the “Company”), a clinical-stage biotechnology company developing long-acting, anti-inflammatory s...
Lyra Therapeutics to Present 52-week Extension Stage Results for ENLIGHTEN 1 Phase 3 Study for LYR-210 for the Treatment of Chronic Rhinosinusitis at COSM 2025
WATERTOWN, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), (“Lyra” or the “Company”), a clinical-stage biotechnology company developing long-acting, anti-inflammatory s...
Lyra Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
– Phase 3 results from ENLIGHTEN 2 pivotal Phase 3 trial of LYR 210 in Chronic Rhinosinusitis (CRS) expected in Q2 2025 – – Phase 3 results from ENLIGHTEN 2 pivotal Phase 3 trial of LYR 210 in Chronic...
Lyra Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
WATERTOWN, Mass., March 13, 2025 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (“Lyra” or the “Company”), a clinical-stage biotechnology company developing long-acting, anti-inflammatory...
Lyra Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
WATERTOWN, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (“Lyra” or the “Company”), a clinical-stage biotechnology company developing long-acting, anti-inflammator...
Lyra Therapeutics Fully Enrolls Pivotal Phase 3 ENLIGHTEN 2 Trial of LYR-210 for the Treatment of Chronic Rhinosinusitis
-- Topline Results Expected Q2 2025 -- WATERTOWN, Mass., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (“Lyra” or the “Company”), a clinical-stage biotechnology company deve...
Lyra Therapeutics to Present Study Results for LYR-210 and LYR-220 in Two Presentations at the ARS and AAO-HNS Annual Meetings
WATERTOWN, Mass., Sept. 27, 2024 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), (“Lyra” or the “Company”), a clinical-stage biotechnology company developing long-acting anti-inflammatory ...
Lyra Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update
– Primary focus continues to be on upcoming results from ENLIGHTEN 1 Phase 3 extension study in 4Q 2024 and ENLIGHTEN 2 pivotal Phase 3 trial in CRS patients in 1H 2025, as planned –
Lyra Therapeutics Announces Cost-Cutting Measures to Preserve Capital
WATERTOWN, Mass., May 21, 2024 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (“Lyra” or the “Company”), today announced that it is advancing its goal to preserve capital by implementing a...
Lyra Therapeutics Reports Topline Results from Phase 3 ENLIGHTEN 1 Trial for LYR-210 in Chronic Rhinosinusitis
ENLIGHTEN 1 trial did not meet its primary endpoint Company plans to evaluate full dataset and path forward WATERTOWN, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (“...
Lyra Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
-- Phase 3 Results from ENLIGHTEN 1 Trial of LYR-210 in Chronic Rhinosinusitis (CRS) Expected in May -- -- Phase 3 Results from ENLIGHTEN 1 Trial of LYR-210 in Chronic Rhinosinusitis (CRS) Expected in...
Lyra Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WATERTOWN, Mass., April 26, 2024 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (the “Company” or “Lyra”), a clinical-stage biotech developing long-acting, anti-inflammatory sinonasal impl...
Lyra Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
-- Data from ENLIGHTEN I Pivotal Phase 3 Trial of LYR-210 in Chronic Rhinosinusitis (CRS) Anticipated Q2 2024 -- WATERTOWN, Mass., March 21, 2024 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: L...
Lyra Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
WATERTOWN, Mass., March 01, 2024 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (“Lyra” or the “Company”), a clinical-stage biotechnology company developing long-acting, anti-inflammatory ...
Lyra Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
– Additional Phase 2 BEACON trial CT scan data demonstrated statistically significant improvement in sinus opacification with LYR-220 and provided radiological evidence of improvement in chronic rhino...
Lyra Therapeutics to Participate in Upcoming Investor Conferences
WATERTOWN, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage biotechnology company developing innovative therapies for the localized treatment of chroni...
Lyra Therapeutics Announces Appointment of Ronan O'Brien as Chief Legal Officer
WATERTOWN, Mass., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (“Lyra” or the “Company”), a clinical-stage biotechnology company developing innovative therapies for the loc...